Recently, we reported on a set of arylpiperazine derivatives with an activity profile on a subgroup of serotonin receptors (5-HT7 and 5-HT1A agonist and 5-HT2A antagonist) specifically designed to obtain prospective drugs for the treatment of the core symptoms of autism spectrum disorder [5]. Here, HTR1A is linked to autism spectrum disorder.